Towson, Maryland Clinical Trials

A listing of Towson, Maryland clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 125 clinical trials
A Phase I First-in-Human Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AZD8701 Administered Intravenously as Monotherapy and in Combination With Durvaluamb (MEDI4736) in Participants With Advanced Solid Tumours.

The purpose of this study is to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Antitumor Activity of AZD8701 Alone and in Combination with Durvalumab (MEDI4736) in Adult Subjects with Select Advanced Solid Tumors

breast cancer
squamous cell carcinoma of head and neck
progressive disease
triple negative breast cancer
lung carcinoma
Research Site
 (7.7 away) Contact site
  • 28 Oct, 2022
  • +12 other locations
A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects With Advanced Malignancies

This trial will look at a drug called SEA-TGT (also known as SGN-TGT) to find out whether it is safe for patients with solid tumors and lymphomas. It will study SEA-TGT to find out what its side effects are. A side effect is anything the drug does besides treating cancer. …

solid tumour
Johns Hopkins Medical Center
 (8.2 away) Contact site
  • 27 Oct, 2022
  • +33 other locations
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors

This is a multicenter, open-label, dose-escalation/dose-expansion Phase 1 clinical study to investigate the safety, tolerability, PK profile, pharmacodynamics, and preliminary clinical efficacy of INCB106385 when given as monotherapy or in combination with INCMGA00012 in participants with selected CD8 T-cell-positive advanced solid tumors including SCCHN, NSCLC, ovarian cancer, CRPC, TNBC, bladder …

cancer of the ovary
measurable disease
bladder tumor
University of Maryland - Greenebaum Cancer Center
 (7.8 away) Contact site
  • 11 Jul, 2022
  • +18 other locations
Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in Infants and Children

Human respiratory syncytial virus (RSV) is a common cause of respiratory illness in infants and children around the world. This study will evaluate the safety and immune response to a RSV vaccine in three groups of participants: healthy children who have already had an RSV infection (RSV seropositive), healthy infants …

antibody titer
respiratory syncytial virus vaccines
Center for Immunization Research (CIR)
 (7.5 away) Contact site
  • 11 Sep, 2021
  • +1 other locations
Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies

The primary objective is to assess the safety and tolerability of TAB004 as monotherapy and in combination with toripalimab in subjects with selected advanced solid malignancies, including lymphoma, and to evaluate the recommended Phase 2 dose. The secondary objectives are to: 1) describe the pharmacokinetic (PK) profile of TAB004 monotherapy …

University of Maryland Medical Center
 (7.8 away) Contact site
  • 15 Jun, 2022
  • +16 other locations
Brain Imaging in Tobacco Smokers During a Quit Attempt

The proposed study will help fill gaps in existing research by determining if nicotine-dependent cigarette smokers show changes in α7 nicotinic acetylcholine receptor (nAChR) availability when compared to matched historical controls using positron emission tomography (PET) imaging and the radioactive ligand [18F]-ASEM (3-(1,4-diazabicyclo[3.2.2]nonan-4-yl)-6 [18F]fluorodibenzo[b,d]thiophene 5,5-dioxide), an α7 nAChR antagonist. The …

brain imaging
pet imaging
positron emission tomography
Accepts healthy volunteers
Johns Hopkins Behavioral Pharmacology Research Unit
 (8.6 away) Contact site
  • 14 Jun, 2022
  • 1 location
SX-682 Treatment in Subjects With Myelodysplastic Syndrome Who Had Disease Progression or Are Intolerant to Prior Therapy

This study will determine the safety profile, maximum tolerated dose (MTD), dose-limiting toxicities (DLT), and recommended Phase 2 dose (RP2D) of SX-682 in the treatment of patients with Myelodysplastic Syndromes (MDS).

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
 (7.6 away) Contact site
  • 18 Mar, 2022
  • +1 other locations
Targeted Imaging of Glutamate Carboxypeptidase II With DCFPyL-PET

To use 18F-DCFPyL imaging agent and PET/CT to detect none prostate cancer solid malignancies and schwannoma tumors.

pet/ct scan
primary cancer
Johns Hopkins University
 (7.6 away) Contact site
  • 04 Mar, 2022
  • 1 location
HPV DNA Vaccine Via Electroporation for HPV16 Positive Cervical Neoplasia

The primary goal of this phase I open label study is to determine the safety and tolerability of pNGVL4aCRTE6E7L2 DNA vaccine, as administered by intramuscular (IM) injection with TriGrid™ electroporation to both HIV- or HIV+ adult female subjects (≥ 19 years), with biopsy confirmed cervical intraepithelial (CIN) II or III …

human papillomavirus
total bilirubin
human papillomavirus dna
hpv vaccine
Johns Hopkins University
 (8.2 away) Contact site
  • 29 Apr, 2022
  • +1 other locations
[18F]FLOR (FC303) PET/CT Imaging in Patients With Prostate Cancer

The study is an open label, single-arm study designed to evaluate the safety and diagnostic performance of [18F]FLOR (FC303) PET/CT imaging to determine the presence or absence of metastatic prostate cancer. .

Johns Hopkins University
 (7.4 away) Contact site
  • 22 Dec, 2021
  • 1 location